ArticleNature communications2026
Measurable residual disease detected by next-generation sequencing in T-cell acute lymphoblastic leukemia.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical utility of measurable residual disease monitoring based on next-generation sequencing in T-cell acute lymphoblastic leukemia remains incompletely defined. Here we show the prognostic value of tracking clonal T-cell receptor gene rearrangements by next-generation sequencing in pediatric patients with T-cell acute lymphoblastic leukemia. Among the 101 patients with trackable clones, measurable residual disease levels at the end of consolidation strongly stratify 4-year event-free survival: 81.6% ± 5.6% for disease levels below 0.0001%, 61.9% ± 11.8% for 0.0001-0.1%, and 45.1% ± 12.1% for levels ≥ 0.1% (P = 0.004). Both T-cell receptor beta and gamma/delta rearrangements demonstrate prognostic significance. Notably, patients with multiparameter flow cytometry-negative but next-generation sequencing-positive measurable residual disease at the end of consolidation have significantly lower 4-year event-free survival compared to those achieving double-negative status (60.8% ± 9.4% vs. 84.9% ± 5.3%, P = 0.038). In conclusion, measurable residual disease monitoring by next-generation sequencing provides superior sensitivity and important clinical value, offering a potential strategy for precise risk stratification in T-cell acute lymphoblastic leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.